SecBot SecBot
SECBOTREPLAY Home › Report › LLY

LLY · Eli Lilly's false advertising lawsuit against Mochi Health and…

ELI LILLY & Co · COURT-RULING filed Sep 7, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 4/10

COURT-RULING filed Sep 7, 2026 at 20:00 ET

Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied dismissal of the UCL conspiracy claim against the Aequita pharmacy defendants (allowing the case to proceed on the core theory that they knowingly participated in an unlawful corporate practice of medicine scheme), but dismissed the Lanham Act false advertising conspiracy claims against all defendants with prejudice (narrowing the scope of the case). This is a modest procedural win for Lilly, the case continues against key defendants on a significant state-law theory, but the federal false advertising conspiracy claims are permanently gone, limiting potential remedies and discovery scope. The ruling is a probability shifter, not a final outcome, and the financial exposure remains unquantified in the opinion.

  • Court denied motion to dismiss UCL conspiracy claim against Aequita Pharmacy and Aequita Corporation defendants, case proceeds on that theory.
  • Court dismissed with prejudice Lanham Act false advertising conspiracy claims against all defendants (Mochi Medical and Aequita entities), Lilly cannot replead without newly discovered facts.
  • Ruling is interlocutory (motion to dismiss on a second amended complaint); no damages awarded or pleaded amount stated in the opinion.
  • Lilly's core allegations of false advertising and corporate practice of medicine against Mochi Health Corp. remain intact and were not challenged in this motion.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access